The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.

Jones, Melanie A; Timms, Kirsten M; Hatcher, Shanell; Cogan, Elizabeth S; Comeaux, Matthew S; Perry, Michael; Morris, Brian; Swedlund, Brad; Elks, Cathy E; Lao-Sirieix, Pierre; Dearden, Simon; Egile, Coumaran; Brown, Jessica S; Harrington, Elizabeth A; Hodgson, Darren; Stern, Matt; Slavin, Thomas P; Mancini-DiNardo, Debora

Jones, Melanie A; Timms, Kirsten M; Hatcher, Shanell; Cogan, Elizabeth S; Comeaux, Matthew S; Perry, Michael; Morris, Brian; Swedlund, Brad; Elks, Cathy E; Lao-Sirieix, Pierre; Dearden, Simon; Egile, Coumaran; Brown, Jessica S; Harrington, Elizabeth A; Hodgson, Darren; Stern, Matt; Slavin, Thomas P; Mancini-DiNardo, Debora.

Afiliação

Jones MA; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Timms KM; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Hatcher S; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Cogan ES; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Comeaux MS; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Perry M; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Morris B; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Swedlund B; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Elks CE; Oncology R&D, AstraZeneca, Cambridge, UK.
Lao-Sirieix P; Oncology R&D, AstraZeneca, Cambridge, UK.
Dearden S; Oncology R&D, AstraZeneca, Cambridge, UK.
Egile C; Oncology R&D, AstraZeneca, Cambridge, UK.
Brown JS; Oncology R&D, AstraZeneca, Cambridge, UK.
Harrington EA; Oncology R&D, AstraZeneca, Cambridge, UK.
Hodgson D; Oncology R&D, AstraZeneca, Cambridge, UK.
Stern M; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Slavin TP; Myriad Genetics, Inc, Salt Lake City, Utah, USA.
Mancini-DiNardo D; Myriad Genetics, Inc, Salt Lake City, Utah, USA.

Genes Chromosomes Cancer ; 62(10): 589-596, 2023 10.

Article em En | MEDLINE | ID: mdl-37222498

Assuntos

Neoplasias da Mama; Neoplasias Ovarianas; Feminino; Humanos; Proteína BRCA1/genética; Neoplasias Ovarianas/genética; Neoplasias Ovarianas/patologia; Proteína BRCA2/genética; Genes BRCA2; Rearranjo Gênico; Reparo do DNA; Sequenciamento de Nucleotídeos em Larga Escala; Neoplasias da Mama/genética; Mutação em Linhagem Germinativa

Palavras-chave

PARP inhibitors; companion diagnostic testing; copy number variants; deletion; duplication; homologous recombination deficiency; large rearrangements; next-generation sequencing; ovarian cancer; tumor testing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama Tipo de estudo: Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google